Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Condition:   Influenza (Healthy Volunteers) Interventions:   Biological: Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains QIV-SD;   Biological: High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northe rn Hemisphere formulation QIV-HD Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials